Inpatient and Outpatient Orderable

Ri Antibody Screen with Reflex to Titer and Western Blot

Synonyms

  • LAB11157
  • Neuronal Nuclear (Ri) Antibody
  • RI ANTIBODY SCREEN WITH REFLEX TO TITER AND WESTERN BLOT
  • RIAB

Cerner Name

Ri Ab Screen reflex to WB and Titer

Clinical Info

Anti-Ri can be detected in patients with theparaneoplastic opsoclonus/myoclonus syndrome. Neoplasms most often associated with Anti-Ri include breast cancer, gynecological cancers, and small cell lung cancer

Specimen Sources

Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

Blood

Specimen Volume

1 mLserum (0.3mL min)

Container

Gold Top Tube

Collection Instructions

Containter/Tube: Gold top tube
Specimen: 1 mLserum (0.3mL min)
Transport Temperature: Refrigerated
Stability: 7 Days Room Temperature
              14 Days Refrigerated
               21 Days Frozen
Patient Preparation: Overnight fasting is preferred
 

Transport Instructions

Refrigerated

Specimen Stability

7 Days Room Temperature
              14 Days Refrigerated
               21 Days Frozen
Patient Preparation: Overnight fasting is preferred
 

Methodology

Immunofluorescence Assay (IFA) • Western Blot (WB)
 
Includes
If Ri Antibody Screen, IFA is positive, Ri Antibody, WB will be performed at an additional charge (CPT code(s): 84181). If Ri Antibody, WB is positive, Ri Antibody, Titer will be performed at an additional charge (CPT code(s): 86256).

Days Performed

Performing Laboratory

Quest Diagnostics' Nichols Institute, Inc. - Chantilly

CPT

86255
 
Set up Monday, Wednesday and Friday
TAT 7 Days

PDM

1959215

Only Orderable at Locations:

Orderable Everywhere

Results
Component Name Base Name Common Name External Name
NEURONAL NUC AB (RI), IFA NEURONUCAB NEURONAL NUC AB RI, IFA Neuronal Nuc Ab (Ri), IFA
RI ANTIBODY, WESTERN BLOT RIAB RI AB, WESTERN BLOT Ri Ab, Western Blot
RI AB TITER RIAB RI AB TITER Ri Ab Titer

Result Interpretation

Ri Ab Screen, IFA  Negative
  Ri Ab, WB    Negative
  Ri Ab, Titer  <1:4
 
This test was developed and its performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

Forms
LAB11157 build edit